We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App





Study Showing Differing COVID-19 Antibody Profiles Among Vaccinated and Naturally Infected Individuals Presented at AACC 2021

By LabMedica International staff writers
Posted on 29 Sep 2021
Print article
Illustration
Illustration

A new study revealing how antibodies against the SARS-CoV-2 virus can vary among recipients of COVID-19 vaccines and naturally infected individuals was presented at the 2021 AACC Annual Scientific Meeting & Clinical Lab Expo.

In the new study, a research group at the University Hospitals Cleveland Medical Center (Cleveland, OH, USA) set out to define differences in antibodies against SARS-CoV-2 among vaccinated and unvaccinated individuals.

The scientists tested for antibodies against the SARS-CoV-2 spike protein, receptor-binding domain (RBD), nucleocapsid protein, and the spike protein’s S1 and S2 subunits in three study groups: 33 fully vaccinated healthcare workers, 52 healthcare workers who had recovered from natural infection, and 34 patients with active infections. The test results revealed that the fully vaccinated individuals had an average of 50-fold higher antibody levels than naturally infected, unvaccinated individuals. Antibodies from the vaccinated group also reacted far more strongly to the RBD and S1 viral antigens, suggesting that antibodies against these proteins could be the best targets for tests developed in the future.

Follow-up studies that profile changes in SARS-CoV-2 antibodies over time for vaccinated individuals and those with breakthrough infections could yield further insights, according to Xiaochun Zhang, MD, PhD, of University Hospitals Cleveland Medical Center. “With the third dose of mRNA vaccine on the horizon, this type of study may help identify practical indicator in optimizing booster-dose planning if an association between antibody level and infection risk is proved,” she said.

Related Links:
University Hospitals Cleveland Medical Center 

Gold Member
Flocked Fiber Swabs
Puritan® Patented HydraFlock®
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Malaria Test
STANDARD Q Malaria P.f/Pan Ag
New
Anti-HHV-6 IgM Assay
anti-HHV-6 IgM ELISA (semiquant.)

Print article
ADLM

Channels

Clinical Chemistry

view channel
Image: The tiny clay-based materials can be customized for a range of medical applications (Photo courtesy of Angira Roy and Sam O’Keefe)

‘Brilliantly Luminous’ Nanoscale Chemical Tool to Improve Disease Detection

Thousands of commercially available glowing molecules known as fluorophores are commonly used in medical imaging, disease detection, biomarker tagging, and chemical analysis. They are also integral in... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Microbiology

view channel
Image: The lab-in-tube assay could improve TB diagnoses in rural or resource-limited areas (Photo courtesy of Kenny Lass/Tulane University)

Handheld Device Delivers Low-Cost TB Results in Less Than One Hour

Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more

Technology

view channel
Image: The HIV-1 self-testing chip will be capable of selectively detecting HIV in whole blood samples (Photo courtesy of Shutterstock)

Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples

As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.